Pautier, Patricia <br/><br/>
Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).  [electronic resource] 

 -  The oncologist  2012 
 - 1213-20 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1549-490X 
<br/><br/><label>Standard No.: </label>10.1634/theoncologist.2011-0467  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Deoxycytidine--analogs & derivatives<br/>Disease-Free Survival<br/>Docetaxel<br/>Dose-Response Relationship, Drug<br/>Female<br/>France--epidemiology<br/>Granulocyte Colony-Stimulating Factor--therapeutic use<br/>Humans<br/>Leiomyosarcoma--drug therapy<br/>Lenograstim<br/>Male<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Neoplasm Recurrence, Local<br/>Recombinant Proteins--therapeutic use<br/>Taxoids--therapeutic use<br/>Uterine Neoplasms--drug therapy<br/>Gemcitabine